Elimination of HPV-associated oropharyngeal cancers in Nordic countries.
Cancer screening
Human papillomavirus
Oropharyngeal cancer
Journal
Preventive medicine
ISSN: 1096-0260
Titre abrégé: Prev Med
Pays: United States
ID NLM: 0322116
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
04
09
2020
revised:
25
01
2021
accepted:
27
01
2021
entrez:
8
3
2021
pubmed:
9
3
2021
medline:
29
6
2021
Statut:
ppublish
Résumé
Incidence of human papillomavirus (HPV, most notably HPV type 16) associated oropharyngeal squamous cell carcinoma (OPSCC) among middle-aged (50-69 year-old) males has tripled in four high income Nordic countries (Denmark, Finland, Norway and Sweden) over the last 30 years. In Finland and Sweden, this increase was preceded by an HPV16 epidemic in fertile-aged populations in the 1980's. The recent implementation of school-based prophylactic HPV vaccination in early adolescent boys and girls will gradually decrease the incidence, and eventually eliminate the HPV-associated OPSCCs (especially tonsillar and base of tongue carcinomas) in the Nordic countries. However, beyond the adolescent and young adult birth cohorts vaccinated, there are approximately 50 birth cohorts (born in 1995 or before) that would benefit from screening for HPV-associated OPSCC. This article reviews the need, prerequisites, proof-of-concept trial and prospects of preventing HPV-associated OPSCC in the Nordic countries.
Identifiants
pubmed: 33678237
pii: S0091-7435(21)00029-3
doi: 10.1016/j.ypmed.2021.106445
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
106445Informations de copyright
Copyright © 2021. Published by Elsevier Inc.